Medical Oncologist
Drug outcomes explained
Olaparib Success Rate: — An Honest Look at the Numbers
When your oncologist prescribes olaparib, you are right to want numbers. This page explains what published trial results actually show, what the word 'median' means for your own situation, and why two patients with the same diagnosis can have very different outcomes.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Medians describe groups, not individuals — Half of all patients in a trial do better than the median result, and half do worse. Neither end is your endpoint.
- Cancer type and BRCA status matter most — Olaparib consistently shows larger effects in BRCA-mutated cancers. A figure from a different population may not apply to you.
- Stable disease is a real success — Olaparib aims to stop or slow growth, not always to shrink tumours. Months of stability on a scan is a meaningful outcome.
- Your markers tell your story — Your CA-125, PSA or scan measurements are what your team actually watches — not the trial average.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Olaparib aims to slow cancer growth rather than eliminate it. How well it works depends on your cancer type and whether you carry a BRCA mutation. NCCN and ASCO guidance links olaparib's strongest evidence to BRCA-mutated cancers. Published trials report a wide range of outcomes — which is why your own test results matter more than any average.
What does 'success rate' actually mean for olaparib?
The phrase 'success rate' covers several different measurements, and which one you are reading matters. Most figures you will find online come from clinical trials and measure how long tumours stay stable or shrink before they start growing again — this is called progression-free survival.
A median progression-free survival figure means that half the patients in that trial did better than this number, and half did worse. It is the midpoint of a group of real people, not a prediction for you specifically.
The range of outcomes around a median is often as useful as the median itself. A wide spread means some patients did far better and some did worse — which tells you that individual results genuinely vary, not that the treatment is unpredictable.
Published figures also depend on who was in the trial. A result from a trial that enrolled only BRCA-mutated ovarian cancer patients tells you very little about olaparib in prostate or pancreatic cancer, and vice versa. Always check what population a figure comes from before applying it to yourself.
How does your team measure whether olaparib is working for you?
Baseline tests before starting
Your team records your tumour markers and performs a scan before or soon after you start. This is the reference point that every later result is compared against.
Starting olaparib as tablets
Olaparib is taken as tablets, usually twice a day. Your team confirms the dose based on your kidney and liver function results.
First marker check at six to eight weeks
Blood markers relevant to your cancer — such as CA-125 in ovarian cancer, or PSA in prostate cancer — are checked early. A falling marker is an encouraging early sign, though some markers lag slightly behind the scan picture.
Imaging at around twelve weeks
A scan is compared to the baseline. The result is classified as the tumour shrinking, staying the same size, or growing.
Ongoing monitoring every two to three months
If the drug is working, regular scans and markers continue. Catching any change early keeps the most options available.
Decision point if the scan changes
If scans show clear growth, your oncologist reviews what comes next. Knowing early — rather than waiting — keeps those next steps manageable.
What should you track between appointments while taking olaparib?
- Write down the date and result of every scan and marker test — ask for a printed copy if one is not offered.
- Note any new side effects or changes since your last appointment, even if they seem minor.
- Tell your team about any new medicine, supplement, herbal preparation or vitamin you have started.
- Mention any planned procedures, including dental work — some interactions need to be managed in advance.
- Ask at each appointment what your latest marker level means compared to where you started.
- Report unusual tiredness or breathlessness rather than assuming it is expected — both have treatable causes.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
Who is most likely to respond to olaparib?
Olaparib's strongest evidence is in cancers that carry a BRCA1 or BRCA2 mutation. These mutations affect a cancer cell's ability to repair a specific kind of DNA damage, and olaparib exploits exactly that weakness. NCCN and ASCO guidance supports its use in BRCA-mutated ovarian, breast, prostate and pancreatic cancers under specific conditions.
Not every patient with these cancer types carries a BRCA mutation. Genetic testing of your blood or tumour tissue is the step that determines whether olaparib is an option for you.
Some patients whose tumours show a broader pattern of DNA repair difficulty — called homologous recombination deficiency, or HRD — may also benefit even without a classic BRCA mutation. Ask your oncologist whether HRD testing was done on your sample and what it showed.
What happens if olaparib stops working?
Olaparib typically works for a period before the cancer develops ways to grow again. This is a known behaviour of most long-term cancer treatments — it is not a failure, and it does not mean you have run out of options.
When scans show progression, your oncologist will discuss the next step. Depending on your cancer type and treatment history, this may include chemotherapy, a different targeted agent, or a clinical trial.
Reporting any change early — a symptom returning, increased pain, something new — gives your team more time to plan rather than respond to a crisis. That time matters.
Did you know?
Olaparib works through a mechanism called synthetic lethality — it is selectively toxic to cancer cells that already have a broken DNA repair pathway, while leaving most normal cells much less affected. This is why its side effect profile looks different from conventional chemotherapy.
The SOLO-1 trial, published in the New England Journal of Medicine, found that a substantial proportion of patients with newly diagnosed BRCA-mutated advanced ovarian cancer had not experienced disease progression at five years with olaparib maintenance — an outcome not seen in the placebo group of the same trial.
Source: SOLO-1 trial (DiSilvestro et al.), New England Journal of Medicine; ESMO Clinical Practice Guidelines for Ovarian Cancer
Explore 75 more Kidney, Ovarian & Sarcoma Targeted Medicines topics
Drug Deep Dive: Olaparib (Lynparza)
- Adjuvant Olaparib After Early Breast Cancer Surgery
- Anaemia and Extreme Fatigue on Olaparib
- Blood Cancer Risk After Long-Term Olaparib: How Real Is It?
- Diet and Nutrition While on Olaparib
- Drug, Food and Supplement Interactions With Olaparib
- Fertility, Pregnancy and Contraception on Olaparib
- How Does Olaparib Work? The PARP Inhibitor Explained
- How Long Does Olaparib Take to Work?
- How Long Will You Stay on Olaparib?
- Maintenance Olaparib: Taking a Drug When There Is No Visible Cancer
- Nausea on Olaparib: Managing the Most Common Side Effect
- Olaparib (Lynparza, Olanib): The Complete Patient Guide
- Olaparib Myths: 'Only for BRCA', 'It's Chemo', 'It Causes Cancer'
- Olaparib Price in India: Brand, Generic and Monthly Cost
- Olaparib Side Effects: The Complete List and Timeline
- Olaparib Success Rate and Survival: An Honest Look at the Numbers
- Olaparib With Bevacizumab or Hormone Therapy: Combination Regimens
- Olaparib in Elderly Patients and Those With Other Illnesses
- Olaparib vs Niraparib vs Talazoparib: Comparing PARP Inhibitors
- Taking Olaparib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Olaparib
- When Olaparib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Olaparib? BRCA-Mutated Ovarian, Breast, Prostate and Pancreatic Cancer
- Will Insurance or a Government Scheme Pay for Olaparib?
- Work, Travel and Daily Life on Olaparib
Drug Deep Dive: Pazopanib (Votrient)
- Diarrhoea and Blood Pressure Rise on Pazopanib
- Diet and Nutrition While on Pazopanib
- Drug, Food and Supplement Interactions With Pazopanib
- Fertility, Pregnancy and Contraception on Pazopanib
- Hair Turning White and Skin Lightening on Pazopanib
- How Does Pazopanib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Pazopanib Take to Work?
- How Long Will You Stay on Pazopanib?
- Liver Toxicity on Pazopanib: Why LFTs Are Checked Every Two Weeks
- Pazopanib (Votrient, Pazonib): The Complete Patient Guide
- Pazopanib Combinations: Why It Is Usually Given Alone
- Pazopanib Myths: Hair Colour, Liver Damage and Stopping Early
- Pazopanib Price in India: Brand, Generic and Monthly Cost
- Pazopanib Side Effects: The Complete List and Timeline
- Pazopanib Success Rate and Survival: An Honest Look at the Numbers
- Pazopanib for Soft Tissue Sarcoma: What It Can and Cannot Do
- Pazopanib in Elderly Patients and Those With Other Illnesses
- Pazopanib in Kidney Cancer vs Sarcoma: Two Different Treatment Goals
- Pazopanib vs Sunitinib: Comparing Toxicity and Quality of Life
- Taking Pazopanib on an Empty Stomach: Why the Timing Rule Exists
- Tests and Monitoring While You Are on Pazopanib
- When Pazopanib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Pazopanib? Kidney Cancer and Soft Tissue Sarcoma
- Will Insurance or a Government Scheme Pay for Pazopanib?
- Work, Travel and Daily Life on Pazopanib
Drug Deep Dive: Sunitinib (Sutent)
- Diet and Nutrition While on Sunitinib
- Drug, Food and Supplement Interactions With Sunitinib
- Fertility, Pregnancy and Contraception on Sunitinib
- Hand-Foot Skin Reaction on Sunitinib: Prevention From Day One
- How Does Sunitinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sunitinib Take to Work?
- How Long Will You Stay on Sunitinib?
- Mouth Sores, Taste Loss and Yellow Skin Discolouration on Sunitinib
- Sunitinib (Sutent, Sunitix): The Complete Patient Guide
- Sunitinib After Kidney Surgery and for GIST: Two Different Settings
- Sunitinib Myths: Hair Colour Change, Dose Cuts and 'Weaker Treatment'
- Sunitinib Price in India: Brand, Generic and Monthly Cost
- Sunitinib Side Effects: The Complete List and Timeline
- Sunitinib Success Rate and Survival: An Honest Look at the Numbers
- Sunitinib and Immunotherapy: Where Combinations Fit in Kidney Cancer
- Sunitinib in Elderly Patients and Those With Other Illnesses
- Sunitinib vs Pazopanib vs Cabozantinib for Kidney Cancer
- Taking Sunitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sunitinib
- The 4-Weeks-On, 2-Weeks-Off Sunitinib Schedule and the 2/1 Alternative
- Thyroid Failure and Fatigue on Sunitinib: The Test to Repeat Every Cycle
- When Sunitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sunitinib? Kidney Cancer, GIST and Pancreatic Neuroendocrine Tumours
- Will Insurance or a Government Scheme Pay for Sunitinib?
- Work, Travel and Daily Life on Sunitinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What is a median survival figure and why does my oncologist use it?
A median is the midpoint of a group — half the patients in a trial had outcomes longer than this number, and half had outcomes shorter. Your oncologist uses it because it is an honest, stable summary of what happened to a large group of real patients. It is not a prediction for you; it is a description of a population. When you read a figure online, check whether that population matches your cancer type, stage and mutation status. A figure from a different group tells you very little about your own situation.
Does olaparib shrink tumours or just stop them growing?
Both can happen. In some patients, tumours shrink — this is called a partial or complete response. In others, tumours stay the same size for a prolonged period without growing, which is called stable disease. Both are meaningful outcomes. For olaparib used as maintenance therapy, stopping growth is usually the primary aim. Months of stable scans are a success, not a disappointment.
Is olaparib used for all BRCA-positive cancers or only certain ones?
Not all BRCA-positive cancers are treated with olaparib. NCCN and ASCO guidance currently supports its use in BRCA-mutated ovarian, breast, prostate and pancreatic cancers under specific conditions — a particular stage, or after a particular prior treatment, for example. Carrying a BRCA mutation is a necessary condition but not a sufficient one on its own. Your oncologist will explain whether your specific diagnosis, stage and treatment history make olaparib appropriate for you.
Will olaparib replace my chemotherapy or run alongside it?
That depends on your situation. In many settings olaparib is used as maintenance therapy — you take it after chemotherapy has finished, to hold the response for as long as possible. In others it is used for a cancer that has already returned. Your oncologist will explain which applies to you. Olaparib is not typically given alongside active chemotherapy in standard practice, though combinations are being studied in clinical trials.
How will I know if olaparib is working for me personally?
Your team monitors the markers specific to your cancer — CA-125 in ovarian cancer, PSA in prostate cancer, or regular imaging in others — and compares each result to your starting level. Falling markers and stable or shrinking tumours on imaging are the signs the drug is working as intended. If you are ever unsure what a result means, ask your oncologist to compare it directly to your baseline. That comparison is far more informative than a single number on its own.
Does olaparib work better when started earlier?
For some cancer types, yes. The strongest evidence for olaparib is in the maintenance setting — starting it after a good response to first-line platinum-based chemotherapy, rather than waiting for the cancer to return. For cancers that have already come back, the evidence is also established but the outcomes differ. Your oncologist will explain which setting applies to you and why the timing was chosen. This is one of the reasons oncologists consider BRCA testing early in the treatment journey rather than later.